All the news Showing 10 of 284 articles from: Access to medicines & diagnosticsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis C Drugs in 2019: Price Drops and Generic Pipeline in Place Hepatitis Central / 16 January 2019 Appeal lodged against decision to uphold Gilead’s patent on hepatitis C drug MSF / 05 December 2018 Belarus to increase purchase of hepatitis C drugs twofold BELTA / 20 November 2018 MPP-AbbVie License on Glecaprevir and Pibrentasvir (G/P): Backtracking on Geographic Coverage but with Options for Oppositions, Compulsory Licenses, and Negotiated Territorial Expansion Health GAP / 20 November 2018 The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir Medicines Patent Pool / 12 November 2018 Malaysia: Govt urged to replenish as Hepatitis C med stock in govt hospitals runs out The Star / 26 October 2018 Brazil court strips Gilead hepatitis drug patent, politician says Reuters / 25 September 2018 EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form Intellectual Property Watch / 16 September 2018 Tahya Misr Fund to provide free doses to 60,000 hepatitis C patients in Egypt Ahram / 11 September 2018 Groups Call for End to Gilead’s Unwarranted Hepatitis C Drug Monopoly in Europe MSF press release / 11 September 2018 ← Prev12345...29Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive